Benzinga’s Top Ratings Upgrades, Downgrades For December 1, 2022
Upgrades Northcoast Research upgraded the previous rating for SpartanNash Co (NASDAQ:SPTN) from Neutral to Buy. SpartanNash earned $0.55…
Redburn Partners Initiates Coverage On Palo Alto Networks with Buy Rating, Announces Price Target of $270
Redburn Partners analyst Nina Marques initiates coverage on Palo Alto Networks (NASDAQ:PANW) with a Buy rating and announces Price Target of $270.
Zelman & Assoc Initiates Coverage On Ferguson with Buy Rating
Zelman & Assoc initiates coverage on Ferguson (NYSE:FERG) with a Buy rating.
New Street Research Initiates Coverage On Mobileye Global with Buy Rating, Announces Price Target of $42
New Street Research analyst Pierre Ferragu initiates coverage on Mobileye Global (NASDAQ:MBLY) with a Buy rating and announces Price Target of $42.
Citigroup Reinstates Buy on ADT, Announces $11 Price Target
Citigroup analyst Peter Christiansen reinstates ADT (NYSE:ADT) with a Buy and announces $11 price target.
JP Morgan Initiates Coverage On Guidewire Software with Overweight Rating, Announces Price Target of $78
JP Morgan analyst Alexei Gogolev initiates coverage on Guidewire Software (NYSE:GWRE) with a Overweight rating and announces Price Target of $78.
Goldman Sachs Initiates Coverage On Altimmune with Buy Rating, Announces Price Target of $20
Goldman Sachs analyst Corinne Jenkins initiates coverage on Altimmune (NASDAQ:ALT) with a Buy rating and announces Price Target of $20.
Goldman Sachs Initiates Coverage On Aclaris Therapeutics with Buy Rating, Announces Price Target of $25
Goldman Sachs analyst Corinne Jenkins initiates coverage on Aclaris Therapeutics (NASDAQ:ACRS) with a Buy rating and announces Price Target of $25.
Goldman Sachs Initiates Coverage On RAPT Therapeutics with Buy Rating, Announces Price Target of $27
Goldman Sachs analyst Corinne Jenkins initiates coverage on RAPT Therapeutics (NASDAQ:RAPT) with a Buy rating and announces Price Target of $27.
JonesTrading Initiates Coverage On Dare Bioscience with Buy Rating, Announces Price Target of $6
JonesTrading analyst Catherine Novack initiates coverage on Dare Bioscience (NASDAQ:DARE) with a Buy rating and announces Price Target of $6.